Talphera (TLPH) Other financing activities (2011 - 2026)
Talphera (TLPH) posted Other financing activities of -$245000.0 for Q2 2026, down 106.07% on a QoQ basis from $4.0 million in Q1 2026, and down 105.63% year-over-year from $4.4 million in Q2 2025.
Analysis
Talphera (TLPH) Other financing activities (2011 - 2026) Analysis & Trends
Talphera has reported Other financing activities for 11 years, with the latest figure at -$245000.0 in Q2 2026.
- On a quarterly basis, Other financing activities fell 105.63% year-over-year to -$245000.0 in Q2 2026; TTM through Jun 2026 was $22.2 million, a 1574.52% increase from a year earlier, with the FY2025 full-year figure at $22.7 million, up 84059.26% from the prior year.
- Other financing activities was -$245000.0 for Q2 2026 at Talphera, down from $4.0 million in the prior quarter.
- The five-year high for Other financing activities was $17.0 million in Q3 2025, with the low at -$5.9 million in Q4 2024.
- Average Other financing activities over 5 years is $2.2 million, with a median of $44500.0 recorded in 2022.
- The largest YoY upside for Other financing activities was 18880.65% in 2024 against a maximum downside of 26522.73% in 2024.
- Over 5 years, Other financing activities stood at $16000.0 in 2022, then plunged by 237.5% to -$22000.0 in 2023, then sank by 26522.73% to -$5.9 million in 2024, then surged by 123.73% to $1.4 million in 2025, then sank by 117.63% to -$245000.0 in 2026.
- The last three Other financing activities figures came in at -$245000.0 (Q2 2026), $4.0 million (Q1 2026), and $1.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.58 Bn | 192.59 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.17 Bn | 176.99 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.59 Bn | 122.74 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.61 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.24 Bn | 55.05 Bn | 1.37 Bn |
| 6 | Moderna | 54.29 Bn | 49.15 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.96 Bn | 29.65 Bn | 992.69 Mn |
| 8 | Biogen | 31.94 Bn | 30.66 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.38 Bn | 29.38 Bn | 1.16 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -245,000.00 |
| Mar 31, 2026 | 4.04 Mn |
| Dec 31, 2025 | 1.39 Mn |
| Sep 30, 2025 | 16.98 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Dec 31, 2024 | -5.86 Mn |
| Mar 31, 2024 | 5.88 Mn |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Mar 31, 2023 | 31,000.00 |
| Sep 30, 2022 | 16,000.00 |
| Mar 31, 2022 | 58,000.00 |
| Sep 30, 2021 | 122,000.00 |
| Jun 30, 2021 | 2,000.00 |
| Mar 31, 2021 | 194,000.00 |
| Sep 30, 2020 | 154,000.00 |
| Jun 30, 2020 | 132,000.00 |
| Mar 31, 2020 | 86,000.00 |
| Dec 31, 2019 | 1,000.00 |
| Sep 30, 2019 | 317,000.00 |